Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAUDIA: Treatment Intensification in Stage II-III Colon Cancer With Positive MRD
NCT05534087Phase 3Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2022
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colon cancer, sponsored by Seoul National University Hospital. Started Dec 2022; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05534087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05534087.